NGS has been on a fascinating journey, featuring numerous pioneering players all racing to get their technology to market. A little over 20 years a...
.png)
Heading into the proactive world of personalised care, data insights are providing us with more effective, targeted and preventative treatments for patients.
NGS has been on a fascinating journey, featuring numerous pioneering players all racing to get their technology to market. A little over 20 years ago, the race began…
Heading into the proactive world of personalised care, data insights are providing us with more effective, targeted and preventative treatments for patients.
Returning from CPhI 2019, in Frankfurt, the words of Eric Langer, President of Bioplan Associates, have stuck with me. Forget the innovation, are biosimilars the real 'workhorse' carrying biopharma to bigger and better things?
Reported to correct 89% of pathogenic human gene variants, prime gene editing has the potential to target over 75,000 different mutations in treatment.
Pharma packaging is in transition. Companies are now pushing boundaries, furthering their offerings and innovating to be seen as true healthcare partners.
Our specialist in lab equipment and technology, Lucy Smith, is looking to get in touch with senior leaders in the life science space to learn more about connectivity.
A new generation of start-ups are revolutionising cancer diagnosis, detecting disease before patients even show symptoms with liquid biopsy tests. This innovation is rife in the US.
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
Globally, sepsis takes six million lives each year. It causes more deaths than breast cancer, lung cancer and stroke combined. Here are five diagnostics companies combating this ugly statistic.
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
There are countless benefits to companion diagnostics including better evidence of clinical utility & greater patient access, more efficient use of resources, better safety and economic advantages for drug companies.
Our Principal Consultant, Adam Butler, talks about the miracles of Stem Cell therapy, the issues surrounding it and the most high-profile case in the treatments' existence.
In an industry as fast paced as the specialty chemicals sector, it's almost impossible to predict the future, but we wanted to try.
Identifying the next big trend in a market like specialty chemicals can be gold dust for any company or individual savvy enough to see it.
In today's hyper-connected world, what's the point of conferences? Our Associate Director Jack Shute asked experts from across the speciality chemical space and some of his CM Life Science colleagues to find out.
Product launches and many fascinating, innovative approaches to diagnostics meant that the 71st meeting of the American Association for Clinical Chemistry did not disappoint.
With a new home, the Minicare I-20 will cement its place as the market leader. As always, this extra competition will encourage innovation among competitors.
Lessons in lateral flow don't come much better than from a founding father of the technology. That's just what we got by speaking with Paul Davis, Co-founder and Chief Scientific Officer at Mologic.
In the last decade the amount of medical data we have access to has exploded. So much so that just interpreting, processing and gaining insights from this data has turned into a whole new area of study and investment - bioinformatics.
It’s no secret that pharmaceutical manufacturing has been on the rise in the East, with both China and India emerging as major manufacturing hubs.
Exciting times lie ahead for companies in the precision medicine software market, as a market growth of 11.5% is expected by 2024.
The diverse and complex world of Pharmaceuticals and Contract Development and Manufacturing Organization (CDMO) is undergoing a fascinating transition.
Pressures on labs have never been greater with problems including an ageing population, increased industry demand and higher global healthcare expenditure.
Since the early 2000’s, before Solexa sequenced bacteriophage phiX-174, single cell genomics has been tipped to become one of the most exciting technologies in genetic analysis.
Working within our broader life science team, I feel lucky to be specialising in the lab equipment space. There seems to be a constant deluge of information, new technology and activity all over the world.
It’s no secret that plastic is in the global bad books at the moment, thanks to admissions like Coca Cola’s last year, that they produced over 3m tonnes of plastic packaging in 2017. That works out at 200,000 bottles a minute.
It’s hard to estimate the total size and value of the diagnostics market, however by looking at some of the forecasts available, the scale of the industry is evident.
Cancer doesn’t always make itself known when it presents itself inside a person. People can live with the disease for a long time and, when symptoms manifest, it can be too late as the cancer has become advanced or has spread.
If one of the global pharma giants develops a new blockbuster drug, they can’t just ship it. They need to perform extensive testing.
There’s always a ‘next big thing’ in the healthcare, research and life sciences industries but the emergence and development of the biotech sector is one of the few that has the chance to change the world.
